Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line
Ebrahim Hosseini1, Seyed Younes Hosseini2, Tayebeh Hashempour3
1Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 1411713116, Iran.
Abstract:
The melanoma differentiation-associated gene‑7 (MDA-7) gene, also termed interleukin‑24 (IL‑24), is a tumor suppressor gene that induces apoptosis in a broad scope of malignant neoplastic cells. The apoptosis induction capacity of the MDA‑7/IL‑24 gene is partially associated with adhering to cognate receptors. The current study aimed to enhance the antitumor effect of IL‑24. The intrinsic signal sequence of IL-24 replaced with a fused artificial signal (secrecon)-RGD4C sequence and its impact was evaluated in HepG2 cells. The modified SP.RGD.IL‑24 and native IL‑24 cDNA sequences were cloned into the pcDNA3.1 expression vector. Subsequently, the expression level, secretion efficacy and targeting propensity of the modified SP.RGD.IL‑24 product compared with normal IL‑24 by were determined by enzyme‑linked immunosorbent assay. The constructs were then transfected into HepG2 and LX‑2 cells as tumor and normal hepatic cell lines, respectively. The expression level of the pro‑apoptotic DNA damage inducible transcript 3 (Gadd153) and BCL2 associated X apoptosis regulator (Bax) genes in the different groups were compared by reverse transcription-quantitative polymerase chain reaction. Additionally, the rate of apoptosis induction of modified and intact IL‑24 sequences was compared by flow cytometry analysis of cells following their propidium iodide/annexin V staining. SP.RGD-IL-24 protein was expressed and secreted in a similar manner to native IL‑24, however, the modified SP.RGD.IL-24 adhered to tumor cells more efficiently than IL‑24 (P<0.05). SP.RGD.IL‑24 significantly induced upregulation of Gadd153 and Bax in HepG2 cells compared with native IL‑24 (P<0.05). However, neither had a significant impact on the expression level of pro-apoptotic genes in LX‑2 cells. Flow cytometry analysis also indicated that modified SP.RGD.IL-24 induced apoptosis more than native IL‑24 in HepG2 cells (P<0.05). In conclusion, the novel generated RGD‑coupled IL-24 construct exhibited sufficient anticancer activity compared with the native IL‑24. The results of the current study provide novel insights for the future of cytokine targeting and indicates its potential capacity as a valuable candidate for gene therapy methods.
Insights
Researchers modified the interleukin-24 (IL-24) gene to enhance its tumor-suppressing ability. The new SP.RGD.IL-24 construct showed improved tumor cell targeting and apoptosis induction in liver cancer cells, offering potential for gene therapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Background:
- Interleukin-24 (IL-24), also known as melanoma differentiation-associated gene-7 (MDA-7), is a tumor suppressor gene.
- IL-24 induces apoptosis in various cancer cells, with its efficacy linked to receptor binding.
- Enhancing IL-24's antitumor effects is a key goal for cancer treatment strategies.
Purpose of the Study:
- To engineer and evaluate a modified IL-24 construct with enhanced antitumor properties.
- To assess the impact of replacing the intrinsic signal sequence of IL-24 with a SP.RGD4C sequence on its expression, secretion, and targeting.
- To compare the efficacy of the modified SP.RGD.IL-24 with native IL-24 in inducing apoptosis in hepatocellular carcinoma cells.
Main Methods:
- The SP.RGD.IL-24 and native IL-24 cDNA sequences were cloned into the pcDNA3.1 expression vector.
- Enzyme-linked immunosorbent assay (ELISA) was used to compare expression and secretion levels.
- HepG2 (cancerous) and LX-2 (normal) cells were transfected to evaluate targeting, apoptosis induction (Gadd153, Bax gene expression via RT-qPCR), and cell death (flow cytometry).
Main Results:
- SP.RGD.IL-24 exhibited similar expression and secretion to native IL-24 but demonstrated significantly enhanced adherence to HepG2 tumor cells.
- The modified construct led to a significant upregulation of pro-apoptotic genes (Gadd153 and Bax) in HepG2 cells compared to native IL-24.
- Flow cytometry confirmed that SP.RGD.IL-24 induced a higher rate of apoptosis in HepG2 cells without affecting normal LX-2 cells.
Conclusions:
- The novel RGD-coupled IL-24 construct (SP.RGD.IL-24) demonstrates potent anticancer activity, surpassing that of native IL-24.
- This engineered cytokine shows enhanced tumor cell targeting and apoptosis induction, validating its potential in gene therapy.
- The findings offer new perspectives for targeted cytokine therapy and its application in cancer treatment.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
